273 related articles for article (PubMed ID: 9110907)
1. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
[TBL] [Abstract][Full Text] [Related]
2. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
3. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
Skinner M; Anderson J; Simms R; Falk R; Wang M; Libbey C; Jones LA; Cohen AS
Am J Med; 1996 Mar; 100(3):290-8. PubMed ID: 8629674
[TBL] [Abstract][Full Text] [Related]
4. Therapy of primary amyloidosis with melphalan and prednisone.
Schwartz RS; Cohen JR; Schrier SL
Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
[TBL] [Abstract][Full Text] [Related]
5. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
Kyle RA; Greipp PR; Garton JP; Gertz MA
Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
J Clin Oncol; 1999 Jan; 17(1):262-7. PubMed ID: 10458241
[TBL] [Abstract][Full Text] [Related]
7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
8. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
10. Primary cardiac amyloidosis with 20-year survival.
Fealey ME; Edwards WD; Grogan M; Dispenzieri A
Cardiovasc Pathol; 2006; 15(6):331-5. PubMed ID: 17113011
[TBL] [Abstract][Full Text] [Related]
11. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
13. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
15. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
16. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
17. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
Benson MD
Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
[TBL] [Abstract][Full Text] [Related]
18. [Primary amyloidosis associated to severe factor X deficiency].
Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
[TBL] [Abstract][Full Text] [Related]
19. [Amyloidosis in a mixed pattern. Sensitivity to colchicine and melphalan].
Frustaci A; Gentiloni N; Feoli F
Minerva Med; 1981 Apr; 72(15):957-60. PubMed ID: 6784038
[TBL] [Abstract][Full Text] [Related]
20. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
[No Abstract] [Full Text] [Related]
[Next] [New Search]
